Evidence Table 4. Risk of bias assessment of trials

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **AuthorYearCountry** | **Randomization adequate?**  | **Allocation concealment adequate?** | **Groups similar at baseline?** | **Eligibility criteria specified?** | **Outcome assessors masked?** | **Care provider masked?** |
| Appleby 1997133 UK | Yes | Unclear | Placebo+1 session counseling younger | Yes | Yes to Drug/No to counseling  | Yes to Drug/No to counseling  |
| Bloch 2012134Israel | Yes | Unclear | Yes | Yes | Yes | Yes |
| Misri 2004135Canada | Yes | Unclear (no details given) | Yes | Yes | Unclear ((Yes at baseline, then for followup: "patient's progress was evaluated by the psychiatrist investigator who administered…) | NA |
| Morrell 2009136UK | Yes | Yes | Yes | Yes | Blinding not possible | Blinding not possible |
| Sharp 2010137 UK | Yes | Yes | Yes | Yes | No | No |
| Wisner 2006138US | Yes | Unclear - it says randomized by a sequence generated by SPSS but it is unclear if people can see the whole list and so would know what the next assignment would be. If they knew the next assignment it would potentially introduce bias because they could change the order they enrolled a patient to get them into the group. | No - more non-white women were assigned to the sertraline group and no other baseline variables reported.  | Yes | Yes | Unclear |
| Yonkers 201287US | Yes | Unclear | Yes, mostly except IDS-SR score different between 2 groups, p<0.05 | Yes | Yes | Yes |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **AuthorYearCountry** | **Patient masked?** | **Intention-to-treat analysis** | **Maintenance of comparable groups** | **Acceptable levels of crossovers, adherence, and contamination?** | **Acceptable levels of overall attrition and between-group differences in attrition?** | **Overall Risk of Bias** |
| Appleby 1997133 UK | Yes except counseling | Yes | Yes | Unclear | Overall attrition 30%, acceptable between group differences in attrition | Medium |
| Bloch 2012134Israel | Yes | Yes | Yes | Yes for adherence and crossover, unclear for contamination | Yes | Medium |
| Misri 2004135Canada | No | Yes for all but EPDS | Yes | Unclear for all | Yes | Medium |
| Morrell 2009136UK | Blinding not possible | No, 418/595 included in primary statistical analysis. No imputation of missing data. | Yes | Unclear | Yes | Medium |
| Sharp 2010137 UK | No | No, At 18 weeks 206/254 included in analysis[19% excluded] | Unclear | Adherence-No, Contamination: No, Crossover: unclear | At 18 weeks, overall attrition acceptable, between group differences: No>10% | High |
| Wisner 2006138US | Yes | Yes for primary, no for secondary | NA, not comparable at baseline | Unclear for all | No - there was 42% attrition in the sertraline group and 24% percent attrition in the nortriptyline group at 8 weeks. This is both high overall and differential attrition.  | High |
| Yonkers 201287US | Yes | No, 44.3% included in the analysis | Yes | High nonadherence: 37% (12 in treatment group, 14 in placebo), Other: unclear | Overall attrition 56%, acceptable between group differences in attrition | High |

NA = not applicable; UK = United Kingdom; US = United States